Kuwait Women’s Health Market Size & Outlook, 2023-2030
Kuwait women’s health market, 2018-2030 (US$M)
Related Markets
Kuwait women’s health market highlights
- The Kuwait women’s health market generated a revenue of USD 122.2 million in 2023 and is expected to reach USD 181.9 million by 2030.
- The Kuwait market is expected to grow at a CAGR of 5.8% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 122.2 million |
| Market revenue in 2030 | USD 181.9 million |
| Growth rate | 5.8% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Kuwait accounted for 0.3% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia women’s health market is projected to lead the regional market in terms of revenue in 2030.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 323.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 36.66% in 2023. Horizon Databook has segmented the Kuwait women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
Kuwait's women’s health market is mainly driven by increasing concerns related to women’s health, high healthcare expenditure per capita, and growing patient pool of target diseases in the country. In Kuwait, about one in five women suffers from endometriosis every year in the country, which is the highest in the world.
Moreover, according to the Journal of Family Medicine and Primary Care article published in June 2023, the prevalence of osteoporosis and osteopenia among Kuwaiti postmenopausal women was 19.3% and 45.6%, respectively.
The growing population in Kuwait, changing lifestyle, and rising health issues are creating demand for advanced healthcare infrastructure in the country. Currently, the country has only one pharmaceutical manufacturing company with a high demand for medicines in the country due to the burden of various diseases, thus creating opportunities for manufacturers to invest in Kuwait.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Kuwait women’s health market size, by application, 2018-2030 (US$M)
Kuwait Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
